Back

Mediators of the benefit of sotagliflozin in patients with worsening heart failure in SOLOIST-WHF

26 August 2023 (16:00 - 16:10)
Organised by: Logo
Congress Presentation Part of: Insights from recent HFpEF trials 1 Pharmacotherapy ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Professor Bertram Pitt

University of Michigan, Ann Arbor (United States of America)

5 More presentations in this session

Presentation thumbnail
Effect of dapagliflozin on outpatient worsening heart failure in patients with mildly reduced or preserved ejection fraction: the DELIVER trial
Doctor S. Chatur (Boston, US)
Abstract Slides Video
Presentation thumbnail
Echocardiographic characterization of patients with supranormal ejection fraction: pooled core laboratory analysis of the TOPCAT and PARAGON-HF trials
Doctor X. Wang (Boston, US)
Abstract Slides Video
Presentation thumbnail
Dietary sodium intake and outcomes: a secondary analysis from SODIUM - HF
Professor C. Saldarriaga (Medellin, CO)
Abstract Slides Video
Presentation thumbnail
Influence of background therapy on efficacy of dapagliflozin in patients with heart failure and improved ejection fraction
Doctor M. Pabon (Boston, US)
Abstract Slides Video
Presentation thumbnail
Effects of empaglifozin on collagen biomarkers in patients with heart failure. Results from the EMPEROR trials
Doctor M. Sumin (Mainz, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Insights from recent HFpEF trials 1
Video

The Event

Event poster

ESC Congress 2023

26 August 2023 16:00 CET
You may be interested in
thumbnail
Congress Presentation
Clinical efficacy of sotagliflozin for heart failure outcomes across cardiac biomarker levels in SCORED
thumbnail
Congress Presentation
Efficacy of sotagliflozin among older adults: a pooled analysis of SCORED and SOLOIST-WHF
thumbnail
Congress Presentation
Effects of oral semaglutide on heart failure outcomes in people with type 2 diabetes and atherosclerotic cardiovascular disease and/or chronic kidney disease participating in SOUL trial

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources